News

News about advances made possible through IPIRA's work, such as innovations commercialized, campus partnerships with industry, and companies born out of licensing UC Berkeley intellectual property rights.

All News

February 9, 2022

BioMADE Funds Pilot Project to De-risk Toxic Product Production in US Bioindustrial Manufacturing

Link

January 3, 2022

Amyris and ImmunityBio Complete Joint Venture for Next Generation COVID-19 RNA Vaccine

Link

November 8, 2021

Amyris Announces Joint Venture Partnership With ImmunityBio For Next Generation COVID-19 RNA Vaccine

https://www.prnewswire.com/news-releases/amyris-announces-jv-partnership...

July 1, 2021

Amyris Completes First Major License For RNA COVID Vaccine Advancing Technology To Human Trials

Link

October 26, 2020

Amyris and The Infectious Disease Research Institute Enter into Exclusive License for Novel RNA Vaccine Platform, Beginning with COVID-19 Vaccine

Link

October 1, 2020

Amyris Delivers Sustainable Alternative To Shark Squalene Adjuvant - Enabling Vaccines for All with No Sharks Killed

Link

July 16, 2015

Amyris Announces Multi-Year, Multi-Million-Dollar Agreement With Global Food Ingredients Supplier

Link

June 3, 2015

Amyris Officially Launches Biossance(TM), its Consumer Beauty Brand

Link

April 15, 2015

Sanofi Wins Patents for Humanity Award from USPTO

Link

October 7, 2014

Airlines Fly the Skies on a Sugar High

Link

August 12, 2014

First antimalarial treatments produced with semisynthetic artemisinin enter market

http://www.path.org/news/press-room/685/

October 11, 2013

Amyris Meets Major Milestone at Its Farnesene Production Facility

Link

April 11, 2013

Launch of antimalarial drug a triumph for UC Berkeley, synthetic biology

Link

December 13, 2004

$43 million grant from Gates Foundation brings together unique collaboration for antimalarial drug

Link